• DISCOVERY
    comes
    from
    within.

    Link alterations to the underlying biology of cancer with unparalleled specificity.

  • ACCURACY
    comes
    from
    within.

    Accurate genomic technologies tailored to solve fundamental challenges in oncology.

  • HOPE
    comes
    from
    within.

    Unlocking actionable information to inform treatment decisions.

  • ACCESS
    comes
    from
    within.

    Partnering to make our novel genomic technologies widely available to patients.

  • SOLUTIONS
    come
    from
    within.

    Offering a portfolio of regulated genomic products for laboratories worldwide.

Innovative genomic solutions
to unlock actionable
information from the genome.

Advanced cancer genome analysis to help researchers identify elusive cancer-related genetic changes.

» View our full suite

Obtain the unique genetic information about an individual tumor and make informed treatment decisions.

» Learn about MYPG

Build high-quality in-house with comprehensive NGS testing and analysis of tissue and plasma.

» See Our Diagnostic Solutions

PHARMA-BIOTECH COMPANIES

Advanced cancer genome analysis to help researchers identify elusive cancer-related genetic changes.

PATIENTS & PHYSICIANS

Obtain unique genetic information about individual tumors and make informed treatment decisions.

MOLECULAR LABORATORIES

Build high-quality in-house with comprehensive NGS testing and analysis of tissue and plasma.

recently posted

Timeline Photos

#WorldCDx takes on Boston. Meet John Simmons, Ph.D., Director of Translational Science & Diagnostics at PGDx TODAY at 3:15PM for a discussion..

latest news & press releases

With the Nobel Prizes around the corner, it’s crystal ball time

Really, we at STAT love autophagy, the cell’s garbage disposal. Also those adorable little molecular machines. Discoveries about the former won the Nobel Prize in medicine last year for Yoshinori Ohsumi, while three inventors of the latter won the chemistry prize. But if... » View

‘Epigenetic’ Changes From Cigarette Smoke May be First Step in Lung Cancer Development

Newswise — Scientists at the Johns Hopkins Kimmel Cancer Center say they have preliminary evidence in laboratory-grown, human airway cells that a condensed form of cigarette smoke triggers so-called “epigenetic” changes in the cells consistent with the earliest steps toward... » View

Sequencing of Circulating Tumor DNA Detects Early Cancers

For their proof-of-principle analysis, published online today in Science Translational Medicine, the researchers did liquid biopsies on 200 individuals with colorectal, breast, lung, or ovarian cancer, and nearly four dozen healthy controls, using an ultra-deep sequencing approach known as targeted error correction sequencing (TEC-Seq)... » View

Personal Genome Diagnostics Awarded Department of Veterans Affairs Contract for Its PlasmaSELECT™ Liquid Biopsy Cancer Profiling Assay

--PGDx's PlasmaSELECT 64 Panel Is the First Non-Invasive Liquid Biopsy Assay Available to Cancer Patients Treated at VA Facilities----Targets 64 Well-Characterized Cancer Genes and Is the Only Liquid Biopsy Panel that Includes Testing for Microsatellite Instability (MSI) for Use in... » View

Personal Genome Diagnostics’ new kind of cancer test is going to be used by the VA

Personal Genome Diagnostics (PGDx) received a new contract from the U.S. Department of Veterans Affairs to provide a test for cancer that does not require tissue samples.The Canton-based company makes a liquid biopsy, which tests for cancer by evaluating 64 genes that are... » View

PGDx Expands Veterans Affairs Agreement to Include Liquid Biopsy Testing

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it will now provide its PlasmaSelect 64 liquid biopsy test to advanced cancer patients receiving treatment at US Department of Veterans Affairs facilities.The agreement makes PGDx the first to provide... » View

Personal Genome Diagnostics Awarded Department of Veterans Affairs Contract for Its PlasmaSELECT Liquid Biopsy Cancer Profiling Assay

--PGDx’s PlasmaSELECT 64 Panel Is the First Non-Invasive Liquid Biopsy Assay Available to Cancer Patients Treated at VA Facilities—--Targets 64 Well-Characterized Cancer Genes and Is the Only Liquid Biopsy Panel that Includes Testing for Microsatellite Instability (MSI) for Use in... » View

PGDx Highlights its Patent -Pending Microsatellite Instability Testing Technology as FDA Approves KEYTRUDA® For MSI Tumors

BALTIMORE, MD, June 2, 2017 – Personal Genome Diagnostics Inc. (PGDx), a pioneer in cancer genomic testing, today highlighted its patent-pending microsatellite instability (MSI) testing technology following the U.S. Food and Drug Administration’s (FDA) accelerated approval of Merck’s immuno-oncology agent... » View

Expanded Keytruda Approval Signals New Phase for Precision Medicine, May Benefit NGS Panel Makers

Subscribe to Molecular DiagnosticsExpanded Keytruda Approval Signals New Phase for Precision Medicine, May Benefit NGS Panel MakersMay 26, 2017|Turna RayPremiumNEW YORK (GenomeWeb) – Over the past decade, as genomics research has transformed understanding of the origins and persistence of cancer,... » View

FDA Landmark Nod: Cancer Drug To Match Tumor Genes, Not Tissue Type

For many years, doctors and researchers have known that cancers in different parts of the body can share genetic abnormalities. For the first time, the FDA has approved a drug based on those abnormalities and not on the organ in... » View

Genomic Predictors of Immunotherapy Response

One of the most cutting-edge pan-cancer biomarkers for response to cancer therapeutics is microsatellite instability (MSI). Resulting from deficient mismatch-repair (MMR), MSI is a clinically relevant condition characterized by the progressive shortening of mononucleotide genomic tracts. With recent advances in... » View

Tumor Evolution: A Resistance Mechanism To Checkpoint Blockade Inhibitors

Tumor cells are readily targeted and destroyed by the body’s army of cytotoxic T cells.  Normally, checkpoint blockade proteins on the outer membrane of T cells, such as programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), distinguish between... » View

Personal Genome Diagnostics’ Expanded PlasmaSELECT™ 64 Is First Liquid Biopsy Pan-Cancer Profiling Panel to Include MSI Analyses for Immuno-Oncology

—First Liquid Biopsy Assay to Include Assessment of Microsatellite Instability Status (MSI), a Surrogate Marker for High Tumor Mutational Load, that Helps Identify Patients Most Likely to Benefit from Treatment with Immuno-Oncology Therapies such as Checkpoint Inhibitors— —Accurately Identifies Clinically... » View

PGDx Details Design of Small-Panel Mutational Burden Test; Plans IVD Development

NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced earlier this month that it is developing a non-invasive next-gen sequencing assay to help identify which cancer patients have the best chance at responding to treatment with immune checkpoint inhibitors.The company received... » View

Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer

 » View

Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors

AbstractInflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer that remains poorly understood at the molecular level. Comprehensive tumor profiling was performed to understand clinically actionable alterations in IBC. Targeted next-generation sequencing (NGS) and IHC were... » View

Latest Publication

Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer

Available on CancerDiscovery

Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have examined the evolving landscape of tumor neoantigens during the emergence of acquired resistance in non-small cell lung cancer patients after initial response to immune checkpoint blockade with anti-PD1 or anti-PD-1/anti-CTLA4 antibodies.

Industry News

New genomic analysis technology has been used to demonstrate how cancer drug resistance evolves

Available on SelectScience

Mark Sausen, PGDx Vice President of Research & Development, commented, "Despite the increased efficacy and durability of treatment seen with IO therapies, some patients develop resistance to the therapy, and this study for the first time elucidates how this may result from the evolving cancer genome landscape..."

latest news & press releases

With the Nobel Prizes around the corner, it’s crystal ball time

Really, we at STAT love autophagy, the cell’s garbage disposal. Also those adorable little molecular machines. Discoveries about the former won the Nobel Prize in medicine last year for Yoshinori Ohsumi, while three inventors of the latter won the chemistry prize. But if... » View

‘Epigenetic’ Changes From Cigarette Smoke May be First Step in Lung Cancer Development

Newswise — Scientists at the Johns Hopkins Kimmel Cancer Center say they have preliminary evidence in laboratory-grown, human airway cells that a condensed form of cigarette smoke triggers so-called “epigenetic” changes in the cells consistent with the earliest steps toward... » View

Sequencing of Circulating Tumor DNA Detects Early Cancers

For their proof-of-principle analysis, published online today in Science Translational Medicine, the researchers did liquid biopsies on 200 individuals with colorectal, breast, lung, or ovarian cancer, and nearly four dozen healthy controls, using an ultra-deep sequencing approach known as targeted error correction sequencing (TEC-Seq)... » View

Personal Genome Diagnostics Awarded Department of Veterans Affairs Contract for Its PlasmaSELECT™ Liquid Biopsy Cancer Profiling Assay

--PGDx's PlasmaSELECT 64 Panel Is the First Non-Invasive Liquid Biopsy Assay Available to Cancer Patients Treated at VA Facilities----Targets 64 Well-Characterized Cancer Genes and Is the Only Liquid Biopsy Panel that Includes Testing for Microsatellite Instability (MSI) for Use in... » View

Personal Genome Diagnostics’ new kind of cancer test is going to be used by the VA

Personal Genome Diagnostics (PGDx) received a new contract from the U.S. Department of Veterans Affairs to provide a test for cancer that does not require tissue samples.The Canton-based company makes a liquid biopsy, which tests for cancer by evaluating 64 genes that are... » View

PGDx Expands Veterans Affairs Agreement to Include Liquid Biopsy Testing

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that it will now provide its PlasmaSelect 64 liquid biopsy test to advanced cancer patients receiving treatment at US Department of Veterans Affairs facilities.The agreement makes PGDx the first to provide... » View

Personal Genome Diagnostics Awarded Department of Veterans Affairs Contract for Its PlasmaSELECT Liquid Biopsy Cancer Profiling Assay

--PGDx’s PlasmaSELECT 64 Panel Is the First Non-Invasive Liquid Biopsy Assay Available to Cancer Patients Treated at VA Facilities—--Targets 64 Well-Characterized Cancer Genes and Is the Only Liquid Biopsy Panel that Includes Testing for Microsatellite Instability (MSI) for Use in... » View

PGDx Highlights its Patent -Pending Microsatellite Instability Testing Technology as FDA Approves KEYTRUDA® For MSI Tumors

BALTIMORE, MD, June 2, 2017 – Personal Genome Diagnostics Inc. (PGDx), a pioneer in cancer genomic testing, today highlighted its patent-pending microsatellite instability (MSI) testing technology following the U.S. Food and Drug Administration’s (FDA) accelerated approval of Merck’s immuno-oncology agent... » View

Expanded Keytruda Approval Signals New Phase for Precision Medicine, May Benefit NGS Panel Makers

Subscribe to Molecular DiagnosticsExpanded Keytruda Approval Signals New Phase for Precision Medicine, May Benefit NGS Panel MakersMay 26, 2017|Turna RayPremiumNEW YORK (GenomeWeb) – Over the past decade, as genomics research has transformed understanding of the origins and persistence of cancer,... » View

FDA Landmark Nod: Cancer Drug To Match Tumor Genes, Not Tissue Type

For many years, doctors and researchers have known that cancers in different parts of the body can share genetic abnormalities. For the first time, the FDA has approved a drug based on those abnormalities and not on the organ in... » View

Genomic Predictors of Immunotherapy Response

One of the most cutting-edge pan-cancer biomarkers for response to cancer therapeutics is microsatellite instability (MSI). Resulting from deficient mismatch-repair (MMR), MSI is a clinically relevant condition characterized by the progressive shortening of mononucleotide genomic tracts. With recent advances in... » View

Tumor Evolution: A Resistance Mechanism To Checkpoint Blockade Inhibitors

Tumor cells are readily targeted and destroyed by the body’s army of cytotoxic T cells.  Normally, checkpoint blockade proteins on the outer membrane of T cells, such as programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), distinguish between... » View

Personal Genome Diagnostics’ Expanded PlasmaSELECT™ 64 Is First Liquid Biopsy Pan-Cancer Profiling Panel to Include MSI Analyses for Immuno-Oncology

—First Liquid Biopsy Assay to Include Assessment of Microsatellite Instability Status (MSI), a Surrogate Marker for High Tumor Mutational Load, that Helps Identify Patients Most Likely to Benefit from Treatment with Immuno-Oncology Therapies such as Checkpoint Inhibitors— —Accurately Identifies Clinically... » View

PGDx Details Design of Small-Panel Mutational Burden Test; Plans IVD Development

NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced earlier this month that it is developing a non-invasive next-gen sequencing assay to help identify which cancer patients have the best chance at responding to treatment with immune checkpoint inhibitors.The company received... » View

Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer

 » View

Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors

AbstractInflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer that remains poorly understood at the molecular level. Comprehensive tumor profiling was performed to understand clinically actionable alterations in IBC. Targeted next-generation sequencing (NGS) and IHC were... » View